General
Preferred name
ALFUZOSIN
Synonyms
ALFUZOSIN HYDROCHLORIDE ()
SL 77499-10 ()
Alfuzosin HCl ()
SL 77499 ()
Xatral ()
Alfuzosin (hydrochloride) ()
SL 77499 HCl ()
ZUFAL XL ()
SL-77-499-10 ()
SL 77 499-10 ()
VASRAN XL ()
ALFUTRAL SR ()
URION S ()
FUZATAL XL ()
Uroxatral ()
XATRAL SR ()
BENESTAN ()
BENESTAN RET ()
KELANU XL ()
SL-77499-10 ()
BESAVAR XL ()
NSC-760065 ()
Alfuzosine ()
Alfuzosina ()
Alfuzosin-d7 ()
P&D ID
PD003155
CAS
81403-68-1
128707-53-9
133880-44-1
1100050-87-0
81403-80-7
1133386-93-2
Tags
available
drug
Approved by
FDA
First approval
2003
Drug indication
Benign prostatic hyperplasia
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive ¦Á1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH)[1][2].
PRICE 31
DESCRIPTION Alfuzosin hydrochloride (Alfuzosin HCl) is an ??1 adrenergic receptor antagonist. It applies to treat benign prostatic hyperplasia (BPH).
DESCRIPTION Alfuzosin is an α1-adrenergic receptor antagonist. (GtoPdb)
DESCRIPTION Alfuzosin (SL 77499-10) is an orally active, selective and competitive ¦Á1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[1][2].
PRICE 33
DESCRIPTION Alfuzosin (SL 77499) is an orally available, competitive ??1-adrenoceptor antagonist.Alfuzosin induces smooth muscle relaxation in the bladder neck and prostate.Alfuzosin has been used to study benign prostatic hypertrophy, lower urinary tract symptoms (LUTS), and ejaculatory dysfunction (EjD).
DESCRIPTION Selective A2A antagonist. Also MAO-B inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Alfuzosin is an alpha-1 adrenergic antagonist used in the symptomatic management of benign prostatic hypertrophy. (Enamine Bioactive Compounds)
DESCRIPTION Alfuzosin hydrochloride (Alfuzosin HCl) is an α1 adrenergic receptor antagonist. It applies to treat benign prostatic hyperplasia (BPH). (TargetMol Bioactive Compound Library)
DESCRIPTION Alfuzosin is a pharmaceutical drug of the alpha-1 blocker class. It works by relaxing the muscles in the prostate and bladder neck. It is used to treat benign prostatic hyperplasia (BPH). It offers an alternative to prostatectomy in patients who require surgery but are unfit for this treatment, and in patients requiring symptomatic relief while awaiting surgery. It is marketed in the United States by Sanofi Aventis under the brand name Uroxatral. It was approved by the FDA for treatment of BPH in June 2003. It has been approved the listing. (BOC Sciences Bioactive Compounds)
DESCRIPTION Alfuzosin (SL 77499) is an orally available, competitive α1-adrenoceptor antagonist.Alfuzosin induces smooth muscle relaxation in the bladder neck and prostate.Alfuzosin has been used to study benign prostatic hypertrophy, lower urinary tract symptoms (LUTS), and ejaculatory dysfunction (EjD). (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
2
Compound Sets
32
AdooQ Bioactive Compound Library
A10052
BOC Sciences Bioactive Compounds
alfuzosin-cas-81403-80-7-item-77837
Cayman Chemical Bioactives
13648
34999
ChEMBL Approved Drugs
CHEMBL1723
CHEMBL709
ChEMBL Drugs
CHEMBL1723
CHEMBL709
Concise Guide to Pharmacology 2017/18
7109
Concise Guide to Pharmacology 2019/20
7109
Concise Guide to Pharmacology 2021/22
7109
Concise Guide to Pharmacology 2023/24
7109
DrugBank
DB00346
DrugBank Approved Drugs
DB00346
DrugCentral
115
DrugCentral Approved Drugs
115
DrugMAP
DMLHOA0
DMZVMKF
DrugMAP Approved Drugs
DMLHOA0
DMZVMKF
DrugMatrix
Enamine Bioactive Compounds
EBC-11209
EUbOPEN Chemogenomics Library
EUB0000967
Guide to Pharmacology
7109
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL709
Mcule NIBR MoA Box Subset
MCULE-9094645643
MedChem Express Bioactive Compound Library
HY-B0192A
HY-B0192
NCATS Inxight Approved Drugs
90347YTW5F
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Alfuzosin-hydrochloride
alfuzosin
TargetMol Bioactive Compound Library
T0091
T22232
Tocris Bioactive Compound Library
3305
VGSC-DB
NA0007
NA0008
External IDs
59
Properties
(calculated by RDKit )
Molecular Weight
389.21
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
2
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
2
cLogP
1.35
TPSA
111.83
Fraction CSP3
0.53
Chiral centers
1.0
Largest ring
6.0
QED
0.65
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Adrenergic Receptor
α-adrenergic receptor
α1A-adrenergic receptor
Primary Target
Adrenergic ?1 Receptors
MOA
Antagonist
alpha1-Adrenoceptor Antagonists
Member status
virtual
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Therapeutic Class
Antihypertensive Agents
VGSC Target
Nav1.5
Solubility
DMSO 85 mg/mL (199 mM)
Water 85 mg/mL (199 mM)
Recommended Cell Concentration
100 nM
Source data